(Brenda) B Leeneman, MSc

Erasmus School of Health Policy & Management

Assistant professor | Health Technology Assessment (HTA)

Email: leeneman@eshpm.eur.nl

Pure profile

Work

Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A. N.Machteld Wymenga, An K.L. Reyners & Carin A. Uyl-de Groot (2024) - Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness - doi: 10.1016/j.ejca.2024.114002 - [link]
Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - doi: 10.1111/ejh.13987 - [link]
M. G. Franken, B. Leeneman, M. J.B. Aarts, A. C.J. van Akkooi, F. W.P.J. van den Berkmortel, M. J. Boers-Sonderen, A. J.M. van den Eertwegh, J. W.B. de Groot, G. A.P. Hospers, E. Kapiteijn, D. Piersma, R. S. van Rijn, K. P.M. Suijkerbuijk, A. A.M. van der Veldt, H. M. Westgeest, M. W.J.M. Wouters, J. B.A.G. Haanen & C. A. Uyl-de Groot (2021) - Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs - doi: 10.1016/j.esmoop.2021.100320 - [link]
Brenda Leeneman (2021) - Evidence-based decision making on drug reimbursement in melanoma: Using real-world evidence to complement evidence from randomized controlled trials
Brenda Leeneman, Kay Schreuder, Carin A. Uyl - de Groot, Alexander C.J. van Akkooi, John B.A.G. Haanen, Marlies Wakkee, Margreet G. Franken & Marieke W.J. Louwman (2021) - Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study - doi: 10.1016/j.ejca.2021.06.007 - [link]
Brenda Leeneman, Hedwig M. Blommestein, Veerle M.H. Coupé, Mathijs P. Hendriks, Wim H.J. Kruit, Peter W. Plaisier, Serge Van Ruth, Albert J. Ten Tije, Michel W.J.M. Wouters, Margreet G. Franken & Carin A. Uyl-De Groot (2021) - Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands - doi: 10.1097/cmr.0000000000000732 - [link]
Brenda Leeneman, Carin Uyl - de Groot, MJB Aarts, ACJ Akkooi, F van den Berkmortel, AJM Van den Eertwegh, JW de Groot, KH Herbschleb, JJ van der Hoeven, GA Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, Astrid van der Veldt, G Vreugdenhil, M Wouters, J Haanen & Margreet Franken (2020) - Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs - doi: 10.3390/cancers12041003
Margreet Franken, Brenda Leeneman, Maria Gheorghe, Carin Uyl - de Groot, JBAG Haanen & Pieter van Baal (2019) - A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma - doi: 10.1016/j.ejca.2019.08.032 - [link]
Brenda Leeneman, Margreet Franken, VMH Coupe, MP Hendriks, Wim Kruit, PW Plaisier, S van Ruth, J Verstijnen, M Wouters, Hedwig Blommestein & Carin Groot (2019) - Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma - doi: 10.1016/j.ejso.2019.01.225 - [link]
Margreet Franken, Brenda Leeneman, A Jochems, MG Schouwenburg, MJB Aarts, ACJ Akkooi, F van den Berkmortel, AJM Van den Eertwegh, JWB de Groot, JJM van der Hoeven, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, G Vreugdenhil, MWJM Wouters, M Zeijl, JBAG Haanen & Carin Uyl - de Groot (2018) - Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands - doi: 10.1097/CAD.0000000000000628 - [link]